Educational only — not medical advice.If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources.Under construction and review—see the updates log.
Primary label indications include: Type 2 diabetes mellitus (adjunct to diet/exercise) (label).
Class: Adjunctive therapy
Common US brands: MOUNJARO
Typical dose range: Typical: 5–15 mg subcutaneously once weekly after titration (start 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; increase in 2.5 mg steps at 4-week intervals if needed) (label).
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2026-03-31
Dosing & forms
Forms/strengths: Single-dose pens for subcutaneous injection once weekly (label).; Dose strengths include 2.5 mg through 15 mg pens (label).
Frequency: Typical: 5–15 mg subcutaneously once weekly after titration (start 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; increase in 2.5 mg steps at 4-week intervals if needed) (label).
Typical range: Typical: 5–15 mg subcutaneously once weekly after titration (start 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; increase in 2.5 mg steps at 4-week intervals if needed) (label).
Mechanism (brief)
Weekly injectable dual [[GIP]]/[[GLP-1]] receptor agonist (tirzepatide) indicated for type 2 diabetes. It produces substantial weight loss in many patients, which can be relevant when metabolic comorbidity complicates psychiatric care, but it has no FDA-approved psychiatric indications.
Metabolism & Half‑life
Metabolism: Proteolytic cleavage of the peptide backbone